BioSpace News Archive

Drug Development

FDA Grants Priority Review to Takeda’s Dengue Vaccine

The FDA granted priority review to Takeda’s Biologics License Application for TAK-003, a dengue vaccine candidate. The vaccine to date is only approved for use in Indonesia.

November 23, 2022
·
2 min read
·
Mark Terry
Business

Breaking the Silos: How One Doctor is Working to Reshape Medicine

BioSpace spoke with Dr. Kiana Aran to discuss her life, her accomplishments and what it means to be a successful woman in science on a global scale.

November 23, 2022
·
4 min read
·
Christie Adams
Drug Development

Arvinas’ Experimental Breast Cancer Drug Fails to Impress Analysts

Late Monday, Arvinas Inc. was forced to divulge the contents of its upcoming breast cancer data presentation, slated for the 2022 San Antonio Breast Cancer Symposium (“SABCS”).

November 23, 2022
·
2 min read
·
Editorial Staff
FDA

FDA Approves CSL-uniQure’s Hemophilia B Gene Therapy, the Most Expensive Medicine in the World

The FDA approved CSL Behring and uniQure’s Hemgenix, a one-time gene therapy developed for adults with Hemophilia B,the companies announced Tuesday afternoon.

November 23, 2022
·
3 min read
·
Rosemary Scott
Business

Novartis and MMV Move to Pivotal Study with New Class of Drug for Malaria

Novartis and Medicines for Malaria Venture are moving into Phase III for a combination treatment targeting the rise of artemisinin-resistant Malaria infection.

November 23, 2022
·
3 min read
·
Kate Goodwin
Drug Development

FDA Adcomm Cancels Meeting on BioMarin’s Hemophilia A Gene Therapy

BioMarin Pharmaceutical announced the FDA no longer plans to hold an advisory committee meeting to review its BLA for Roctavian an AAV gene therapy for adults with severe hemophilia A.

November 23, 2022
·
2 min read
·
Rosemary Scott
Business

Xeris Biopharma Announces Research Collaboration and Option Agreement With Horizon Therapeutics plc for XeriJect™ Formulation of Teprotumumab

Xeris Biopharma Holdings, Inc. today announced that it has entered into a research collaboration and option agreement with Horizon Therapeutics plc (Nasdaq: HZNP).

November 23, 2022
·
7 min read
BioCapital

Immunocore to present at the 5th Annual Evercore ISI HealthCONx Conference

Immunocore Holdings Plc today announced that management will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference.

November 23, 2022
·
1 min read
Biotech Bay

Sutro Biopharma to Participate in Upcoming Investor Conferences

Sutro Biopharma, Inc. today announced that Bill Newell, Chief Executive Officer, will participate in two upcoming investor conferences.

November 23, 2022
·
2 min read
Deals

Nordic Nanovector: Invitation to webcast regarding proposed merger with APIM Therapeutics

Nordic Nanovector ASA will host a webcast, including a question and answers session on Thursday, November 24 at 4.30 P.M. CET.

November 23, 2022
·
3 min read